Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Rachel L. Stewart, DO, PhD

Why are there no ratings?
Dr. Rachel Stewart


  • Pathology and Laboratory Medicine
  • About

    Faculty Rank

    Assistant Professor of Pathology and Laboratory Medicine


    Touro University College of Osteopathic Medicine, Vallejo, Calif.


    Anatomic and Clinical Pathology, University of Kentucky


    Molecular Genetic Pathology, University of Utah, ARUP Laboratories, School of Medicine, Salt Lake City

    Certifications and Special Training

    American Board of Pathology, Anatomic and Clinical Pathology

    American Board of Pathology, Molecular Genetic Pathology

Are you happy with the care you received from this provider?

Please let us know by filling out a patient satisfaction survey when you get one. You can also leave an online review by clicking the button below.

Leave a review
  • Publications

    1. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G. Hum Pathol. 2019 Feb 19;. doi: 10.1016/j.humpath.2019.02.001. [Epub ahead of print] PubMed PMID: 30794891.
    2. Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists. Bui MM, Riben MW, Allison KH, Chlipala E, Colasacco C, Kahn AG, Lacchetti C, Madabhushi A, Pantanowitz L, Salama ME, Stewart RL, Thomas NE, Tomaszewski JE, Hammond ME. Arch Pathol Lab Med. 2019 Jan 15;. doi: 10.5858/arpa.2018-0378-CP. [Epub ahead of print] PubMed PMID: 30645156.
    3. Potential protein markers for breast cancer recurrence: a retrospective cohort study. He C, Plattner R, Rangnekar V, Zhou B, Liu C, Stewart RL, Huang B, Wang C, Tucker TC. Cancer Causes Control. 2019 Jan;30(1):41-51. doi: 10.1007/s10552-018-1099-8. Epub 2018 Nov 28. PubMed PMID: 30488343; NIHMSID:NIHMS1515270.
    4. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Liu J, Duan Z, Guo W, Zeng L, Wu Y, Chen Y, Tai F, Wang Y, Lin Y, Zhang Q, He Y, Deng J, Stewart RL, Wang C, Lin PC, Ghaffari S, Evers BM, Liu S, Zhou MM, Zhou BP, Shi J. Nat Commun. 2018 Dec 5;9(1):5200. doi: 10.1038/s41467-018-07258-y. PubMed PMID: 30518851; PubMed Central PMCID: PMC6281582.
    5. Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance. Xiong G, Stewart RL, Chen J, Gao T, Scott TL, Samayoa LM, O'Connor K, Lane AN, Xu R. Nat Commun. 2018 Oct 26;9(1):4456. doi: 10.1038/s41467-018-06893-9. PubMed PMID: 30367042; PubMed Central PMCID: PMC6203834.
  • Research

    Cancer Center Member

    Research Focus

    Biomarker Development and Molecular Oncology


    • Cancer Cell Biology and Signaling

    College & Department

    • College of Medicine
    • Department of Pathology and Laboratory Medicine